# Chongqing University Cancer Hospital: Phase 2 study in Rectal Cancer Patients, Locally Advanced Rectal Cancer (LARC) (100 participants)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Chongqing University Cancer Hospital |
| Sponsor type | Academic and hospital |
| Study | NeoCSR-Omics Trial: CAPOX + Serplulimab Before vs. After Short-course RT in LARC |
| NCT ID | NCT07898865 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Rectal Cancer Patients; Locally Advanced Rectal Cancer (LARC) |
| Intervention types | radiation, drug |
| Target enrollment | 100 |
| Site countries | China |
| Posted | 2026-10-27 |
| Planned start | 2025-10-16 |
| Event | Newly registered study |
| Event date | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Phase 2: multi-site, larger budget.
- 100 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07898865). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.